Translational Research in Oncology
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bcirg.org
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
- Conditions
- Anal Squamous Cell CarcinomaColorectal NeoplasmsCastrate Resistant Prostate CancerNeuroendocrine Carcinoma of ProstateGastroenteropancreatic Neuroendocrine NeoplasmSoft Tissue SarcomaMalignant Pleural MesotheliomaSmall Cell Lung Carcinoma
- Interventions
- Combination Product: Regorafenib in combination with Tislelizumab
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Translational Research in Oncology
- Registration Number
- NCT05582031
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Procedure: Loco-regional therapy
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 496
- Registration Number
- NCT04777851
- Locations
- 🇺🇸
UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
🇧🇪UCL SAINT LUC - UC Louvain, Brussels, Belgium
🇧🇪Antwerp University Hospital, Edegem, Belgium
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT04261218
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT03004534
- Locations
- 🇺🇸
Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach, California, United States
🇩🇪Universitatsklinikum Erlangen, Erlangen, Germany
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 34
- Registration Number
- NCT02900560
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸UCLA, Los Angeles, California, United States
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 44
- Registration Number
- NCT02115048
- Locations
- 🇧🇦
University Hospital Clinical Center Banja Luka, Oncology Clinic, Banja Luka, Bosnia and Herzegovina
🇺🇸DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States
🇪🇸Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 54
- Registration Number
- NCT00777049
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00777335
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- Interventions
- Biological: AMG 479
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT00719212
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇪🇸Hospital U 12 de Octubre, Madrid, Spain
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 170
- Registration Number
- NCT00718523
- Locations
- 🇺🇸
Hope A Women's Cancer Center, Asheville, North Carolina, United States
🇺🇸Central Hematology Oncology Medical Group Inc., Alhambra, California, United States
🇺🇸Hematology and Oncology Specialists, LLC, Metairie, Louisiana, United States